Literature DB >> 1720035

Adhesive functions of platelets lacking glycoprotein IV (CD36).

N N Tandon1, C F Ockenhouse, N J Greco, G A Jamieson.   

Abstract

Glycoprotein IV (GPIV; CD36 or GPIIIb) is a cell surface glycoprotein that has been proposed as mediating a number of physiologically important processes such as the adhesion of platelets to thrombospondin (TSP) and collagen, the cytoadherence of Plasmodium falciparum-infected erythrocytes, and the TSP-dependent interaction of monocytes with platelets and macrophages. Because platelets of the Naka-negative phenotype have recently been shown to lack detectable GPIV, their availability offered the opportunity to test directly these hypotheses regarding its adhesive functions. It has been found that Naka-negative platelets and monocytes do not support cytoadherence of P falciparum-infected erythrocytes. Naka-negative platelets are deficient in the initial stages of their adhesion to fibrillar collagen and this defect is most marked under Mg(2+)-free conditions. Finally, the ability of Naka-negative platelets to bind TSP before or after activation is unimpaired as compared with normal controls. These results do not support a role for GPIV as the TSP receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Thrombospondin-platelet interactions. Role of divalent cations, wall shear rate, and platelet membrane glycoproteins.

Authors:  F R Agbanyo; J J Sixma; P G de Groot; L R Languino; E F Plow
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

3.  Antigenic and functional differences in adhesion of Plasmodium falciparum-infected erythrocytes to human and bovine CD36.

Authors:  C F Ockenhouse; N N Tandon; G A Jamieson; D E Greenwalt
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

4.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

Authors:  Jeff S Isenberg; Martin J Romeo; Christine Yu; Christine K Yu; Khauh Nghiem; Jude Monsale; Margaret E Rick; David A Wink; William A Frazier; David D Roberts
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 5.  The role of platelets in the pathogenesis of cerebral malaria.

Authors:  Dermot Cox; Sam McConkey
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

Review 6.  Platelet hyperreactivity, scavenger receptors and atherothrombosis.

Authors:  M Valiyaveettil; E A Podrez
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

7.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.

Authors:  Eugene A Podrez; Tatiana V Byzova; Maria Febbraio; Robert G Salomon; Yi Ma; Manojkumar Valiyaveettil; Eugenia Poliakov; Mingjiang Sun; Paula J Finton; Brian R Curtis; Juhua Chen; Renliang Zhang; Roy L Silverstein; Stanley L Hazen
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

Review 8.  Targeting CD36 as Biomarker for Metastasis Prognostic: How Far from Translation into Clinical Practice?

Authors:  Ana-Maria Enciu; Eugen Radu; Ionela Daniela Popescu; Mihail Eugen Hinescu; Laura Cristina Ceafalan
Journal:  Biomed Res Int       Date:  2018-07-04       Impact factor: 3.411

Review 9.  CD36 tango in cancer: signaling pathways and functions.

Authors:  Jingchun Wang; Yongsheng Li
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

10.  Experimental conditions affect the outcome of Plasmodium falciparum platelet-mediated clumping assays.

Authors:  Mònica Arman; J Alexandra Rowe
Journal:  Malar J       Date:  2008-11-24       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.